Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2010

View Archived Issues

DDP IV inhibitor ASP-4000 has long-lasting effects in preclinical studies

Liposomal amphotericin B is noninferior to conventional therapy in visceral leishmaniasis

Preclinical studies point to potential of NB-003 in treating acne

AG-2 described as new biomarker for ovarian cancer

Albumin therapy to be evaluated in acute ischemic stroke in ongoing phase III trial

AstraZeneca discloses novel JAK2 inhibitors for cancer therapy

GlaxoSmithKline presents new interferon inducers

Merck & Co. describes novel gamma-secretase modulators

NeuroSearch patents new nicotinic acetylcholine alpha7 receptor modulators

Aastrom treats final patient in phase II trial of cardiac repair cells in dilated cardiomyopathy

Lundbeck reports on fourth quarter 2009, ended December 31

Actelion receives FDA's complete response letter on Zavesca sNDA for Niemann-Pick type C disease

Abbott to acquire Facet Biotech

FDA recommends approval InterMune's Esbriet for idiopathic pulmonary fibrosis

FDA approves Botox for upper limb spasticity in adults

Thymosin beta-4 improves neurological outcome in rat model of stroke

Diamyd Medical advances U.S. phase III trial of Diamyd for diabetes type 1

Limerick BioPharma reports positive phase Ia data on LIM-0705

Cempra completes phase I trials of CEM-101 for community-acquired bacterial pneumonia

Cellzome and GSK enter strategic drug discovery alliance in inflammatory disease

Transgene signs exclusive option agreement with Novartis for NSCLC therapeutic TG-4010

FDA grants orphan drug status to Cytokinetics' CK-2017357 in ALS

Affymax receives milestone payment from Takeda for phase III Hematide trial in Japan

ImmunoCellular's CSC-based vaccine ICT-121 increases survival in animal model of glioblastoma

AMT's gene therapy agent for hemophilia B begins phase I/II trial

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026